710336-81-5

Upstream product

• 139-85-5 3,4-dihydroxybenzaldehyde 

Downstream Products

• 1131450-90-2 (3S,4R)-phenyl-3-((2,2-d2-benzo[d][1,3]dioxolo-5-yloxy)methyl-d2)-4-(4-fluorophenyl)piperidine-1-carboxylate 
• 1131450-88-8 (3S,4R)-4-phenyl 3-((2,2-d2-benzo[d][1,3]dioxol-5-yloxy)methyl)-4-(4-fluorophenyl)piperidine-1-carboxylate 
• 1131450-96-8 2-(2,2-d2-benzo[d][1,3]dioxol-5-yl)-N-(2,3-(dimethoxy-d6)benzyl)ethanamine 
• 1131450-95-7 (Z)-2-(2,2-d2-benzo[d][1,3]dioxol-5-yl)-N-(2,3-(dimethoxy-d6)-benzylidene)ethanamine 
• 1005412-32-7 (3S,4R)-3-((2,2-d2-benzo[d][1,3]dioxol-5-yloxy)methyl-d2)-4-(4-fluorophenyl)-1-methylpiperidine 
• 923932-43-8 (3S,4R)-3-((2,2-d2-benzo[d][1,3]dioxol-5-yloxy)methyl)-4-(4-fluorophenyl)piperidine 
• 923932-45-0 (3S,4R)-3-((2,2-d2-benzo[d][1,3]dioxol-5-yloxy)methyl-d2)-4-(4-fluorophenyI)piperidine 
• 923932-15-4 (3S,4R)-3-((benzo[d][1,3]dioxol-(2,2-d2)-5-yloxy)methyl)-4-(4-fluorophenyl)piperidine hydrochloride 
• 1005412-34-9 (3S,4R)-4-nitrophenyl 3-((benzo[d][1,3]dioxol-(2,2-d2)-5-yloxy)methyl)-4-(4-fluorophenyl)piperidine-1-carboxylate 
• 936838-88-9 (3S,4R)-3-((benzo[d][1,3]dioxol-(2,2-d2)-5-yloxy)methyl)-4-(4-fluorophenyl)-1-methylpiperidine 

Relevant academic research and scientific papers

Altering metabolic profiles of drugs by precision deuteration: Reducing mechanism-based inhibition of CYP2D6 by Paroxetine

Selective deuterium substitution as a means of ameliorating clinically relevant pharmacokinetic drug interactions is demonstrated in this study. Carbon-deuterium bonds are more stable than corresponding carbon-hydrogen bonds. Using a precision deuteration platform, the two hydrogen atoms at the methylenedioxy carbon of paroxetine were substituted with deuterium. The new chemical entity, CTP-347 [(3S,4R)-3-((2,2-dideuterobenzo[d][1,3]dioxol-5-yloxy)me thyl)-4-(4-fluorophenyl)piperidine], demonstrated similar selectivity for the serotonin receptor, as well as similar neurotransmitter uptake inhibition in an in vitro rat synaptosome model, as unmodified paroxetine. However, human liver microsomes cleared CTP-347 faster than paroxetine as a result of decreased inactivation of CYP2D6. In phase 1 studies, CTP-347 was metabolized more rapidly in humans and exhibited a lower pharmacokinetic accumulation index than paroxetine. These alterations in the metabolism profile resulted in significantly reduced drug-drug interactions between CTP-347 and two other CYP2D6-metabolized drugs: tamoxifen (in vitro) and dextromethorphan (in humans). Our results show that precision deuteration can improve the metabolism profiles of existing pharmacotherapies without affecting their intrinsic pharmacologies.

SYNTHESIS OF DEUTERATED CATECHOLS AND BENZO[D][1,3] DIOXOLES AND DERIVATIVES THEREOF

The present invention provides a convenient and efficient process for the synthesis of d2-benzo[d][l,3]dioxoles.